JEITO CAPITAL becomes key investor in NMD Pharma as part of a €35 Million new financing - Jeito
Eva Chin - Chief Development Officer at NMD Pharma | The Org
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
PDF) Extracellular magnesium and calcium reduce myotonia in C1C-1 inhibited rat muscle
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
PDF) Applicability of Cable Theory to Vascular Conducted Responses | Lars Jensen - Academia.edu
Within-sibship genome-wide association analyses decrease bias in estimates of direct genetic effects | Nature Genetics
Annual Report 2019 by Lundbeckfonden - Issuu
NMD Pharma
Thomas Holm Pedersen - Crunchbase Person Profile
NMD Pharma Org Chart | The Org
Convention Speakers - Global CMT Research Convention
Chloride channel inhibition improves neuromuscular function under conditions mimicking neuromuscular disorders - Pedersen - 2021 - Acta Physiologica - Wiley Online Library
The SLC9A-C Mammalian Na+/H+ Exchanger Family: Molecules, Mechanisms, and Physiology | Physiological Reviews
Agenda - Neurotech Partnering
Structure-Based Design of Novel Biphenyl Amide Antagonists of Human Transient Receptor Potential Cation Channel Subfamily M Memb
Agenda - Neurotech Partnering
NMD Pharma A/S | LinkedIn
JPM | Free Full-Text | Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders
Thomas Holm Pedersen - Crunchbase Person Profile
Members' Meeting: State of the Union – Late Stage Financing – Crossover & IPOs | DANISH BIO – DANSK BIOTEK
Other news — NMD Pharma
Cu2O/CuS Nanocomposites Show Excellent Selectivity and Stability for Formate Generation via Electrochemical Reduction of Carbon Dioxide | ACS Materials Letters
HITTA ER ET A UN AMI TA ON HI HA UT ME AT THE
Annual Report 2018 by Lundbeckfonden - Issuu
